This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

9 Health Care Stocks With 100% Buy Ratings

NEW YORK ( TheStreet) -- Transcend Services (TRCR), Emergent BioSolutions (EBS - Get Report), Athersys (ATHX) and MediciNova (MNOV) are among 9 stocks with 100% buy ratings from analysts.

In comparison, pharma giants Johnson & Johnson (JNJ), Pfizer (PFE), Merck (MRK), Abbott Laboratories (ABT) and Bristol Myers Squibb (BMY) have buy ratings in the range of 30%-70%.

In addition, analysts expect these nine stocks to outperform their peers and broader markets, based on the upside implied from their respective 12-month price targets. These stocks have an implied upside potential of 5%-331% with a mean upside value of around 92%.

9. Transcend Services (TRCR) is a medical transcription company in the U.S. engaged in developing and utilizing a range of technology solutions to support the transcription process, including robust voice capture systems and speech recognition technology. The company will announce its first quarter results on May 5.

Net income for the first quarter of 2011 is forecast at $3.3 million on sales of $28.9 million, compared to a net income of $1.6 million on $22.2 million sales recorded during 2010 first quarter, according to analysts polled by Bloomberg. Earnings per share are pegged at 28 cents, up from 15 cents per share reported during the comparable quarter last year.

The company recently completed the acquisition of DTS America for $9.5 in cash. Transcend will not assume any debt. The transaction is expected to have a nominal negative impact on second quarter 2011 earnings per share in the $0.00-$0.01 per share range due to transaction costs, and would be accretive to earnings per share starting third quarter of 2011.

All the four analysts covering the stock rate a buy on it. The stock has 5% upside over the next 12 months with a consensus target price of $25, analysts polled by Bloomberg envisage. The stock has gained 60% during the past one year.

1 of 9

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
PATH $0.00 0.00%
ALIM $4.83 -2.20%
EBS $30.50 -0.36%
HSTM $31.19 0.55%
ICUI $88.00 -0.30%


DOW 18,130.02 +49.88 0.28%
S&P 500 2,121.67 +3.98 0.19%
NASDAQ 5,102.6690 +10.5840 0.21%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs